Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients aged 18 years or older at index.
Patients with RMS, including clinically isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS), and secondary progressive multiple sclerosis (SPMS) at the time of initiating anti-CD20 treatment.
Newly initiated anti-CD20 treatment after March 2017 (no history of anti-CD20 therapy at any time in medical record before this date) to the latest data cutoff (November 2022).
Patients with at least one documented IgG lab value pre- and post-anti-CD20 drug initiation.
You may not be if
Patients with diagnosis of primary progressive multiple sclerosis (PPMS) prior to anti-CD20 treatment.
Participated in an anti-CD20 drug clinical trial during the study period.
Clareo Health | Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies
